{
    "nctId": "NCT00973557",
    "briefTitle": "The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function",
    "officialTitle": "The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function",
    "overallStatus": "COMPLETED",
    "conditions": "Colorectal Cancer, Lung Cancer, Breast Cancer, Glioblastoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "To determine whether the drug, Bevacizumab (a monoclonal anti VEGF-A antibody), which is approved to treat patients with metastatic colon cancer induces hyperprolactinemia (increased prolactin secretion) in humans with intact pituitary function.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month\n* Adults (18 years of age or older)\n\nExclusion Criteria:\n\n* Patients who are taking medications known to affect serum prolactin levels\n* Patients who are pregnant\n* Patients who have pituitary disease\n* Minors (Under the age of 18)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}